Ab­b­Vie beats ex­pec­ta­tions with small­er Hu­mi­ra slide — and big gains for next au­toim­mune block­busters

Hu­mi­ra isn’t go­ing any­where yet. And its suc­ces­sors are com­ing along nice­ly, too.

On Thurs­day, Ab­b­Vie shared sec­ond-quar­ter fi­nan­cial re­sults that show its cor­ner­stone im­munol­o­gy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER